Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs AZD 5423 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.